LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 255

Search options

  1. Article ; Online: Disease Clearance is not Synonymous with Cure.

    D'Amico, Ferdinando / Peyrin-Biroulet, Laurent / Danese, Silvio

    Inflammatory bowel diseases

    2023  Volume 30, Issue 3, Page(s) 509

    MeSH term(s) Humans ; Colitis, Ulcerative ; Consensus ; Mutation
    Language English
    Publishing date 2023-10-05
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1340971-2
    ISSN 1536-4844 ; 1078-0998
    ISSN (online) 1536-4844
    ISSN 1078-0998
    DOI 10.1093/ibd/izad236
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?

    D'Amico, Ferdinando / Peyrin-Biroulet, Laurent / Danese, Silvio

    United European gastroenterology journal

    2023  Volume 11, Issue 8, Page(s) 717–719

    MeSH term(s) Humans ; Colitis, Ulcerative/complications ; Colitis, Ulcerative/diagnosis ; Colitis, Ulcerative/drug therapy ; Crohn Disease/therapy ; Inflammatory Bowel Diseases
    Language English
    Publishing date 2023-07-03
    Publishing country England
    Document type Editorial
    ZDB-ID 2728585-6
    ISSN 2050-6414 ; 2050-6406
    ISSN (online) 2050-6414
    ISSN 2050-6406
    DOI 10.1002/ueg2.12436
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: MMX mesalamine in ulcerative colitis: Major advantages towards classical mesalamine formulations.

    D'Amico, Ferdinando / Lusetti, Francesca / Peyrin-Biroulet, Laurent / Danese, Silvio

    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

    2024  

    Abstract: Medical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed ... ...

    Abstract Medical therapy is the cornerstone of ulcerative colitis (UC) management and aims to induce and maintain remission. In case of mild-to-moderate UC, mesalamine (5-ASA) is the first-line option. 5-ASA requires local release at the level of the inflamed mucosa to exert its therapeutic action. While rectal preparations are useful in distal colitis, in cases of UC of at least rectosigmoid extent, guidelines suggest the association of oral and rectal 5-ASA. Mesalamine with Multi Matrix System® technology (MMX mesalamine) is an oral, high-strength (1.2 g/tablet), once-daily formulation of 5-ASA, designed to provide delayed and prolonged release throughout the entire colon. Clinical trials demonstrated a strong efficacy in inducing and maintaining clinical and endoscopic remission in active mild-to-moderate UC. The efficacy is related to specific colonic drug-delivery, to its high-dosage and once-daily administration, thus improving patients' adherence and outcomes. The specific colonic-delivery is also associated with very low rates of systemic absorption and adverse events (AEs). With this comprehensive review we aimed to summarize current knowledge on MMX mesalamine in mild-to-moderate UC, in terms of clinical pharmacology, efficacy and safety, also compared to other 5-ASA products. In addition we provided an expert opinion on the topic, examining the implications on clinical practice.
    Language English
    Publishing date 2024-05-04
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 1459373-7
    ISSN 1878-3562 ; 1125-8055
    ISSN (online) 1878-3562
    ISSN 1125-8055
    DOI 10.1016/j.dld.2024.04.012
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article: Drug Optimization in Patients with Mild-to-Moderate Ulcerative Colitis: A Global Survey.

    D'Amico, Ferdinando / Jairath, Vipul / Paridaens, Kristine / Peyrin-Biroulet, Laurent / Danese, Silvio

    Journal of clinical medicine

    2024  Volume 13, Issue 9

    Abstract: Background/ ... ...

    Abstract Background/Objectives
    Language English
    Publishing date 2024-04-24
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm13092510
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials.

    Neurath, Laura / D'Amico, Ferdinando / Danese, Silvio

    Expert opinion on emerging drugs

    2023  Volume 28, Issue 1, Page(s) 27–42

    Abstract: Introduction: Current therapeutic options for patients with ulcerative colitis comprise monoclonal antibodies against tumor necrosis factor (TNF), alpha4/beta7 integrin, and interleukin (IL)12/23 as well as small molecules such as tofacitinib, ... ...

    Abstract Introduction: Current therapeutic options for patients with ulcerative colitis comprise monoclonal antibodies against tumor necrosis factor (TNF), alpha4/beta7 integrin, and interleukin (IL)12/23 as well as small molecules such as tofacitinib, upadacitinib, ozanimod, and filgotinib. However, many patients fail to respond to these agents or have loss of response over time. Therefore, there is a large unmet clinical need for new therapeutic agents.
    Areas covered: Here, we review recent phase 2/3 studies in active ulcerative colitis and discuss preliminary data on the efficacy (clinical, endoscopic, and histologic remission) and safety of novel drugs including Janus kinase (JAK) inhibitors, IL23 blockers, integrin inhibitors, and S1P1R modulators.
    Expert opinion: We highlight the potential impact of these agents for the future therapeutic landscape of this disease with special emphasis on clinical impact, unmet needs, safety aspects, and advanced combination therapy.
    MeSH term(s) Humans ; Antibodies, Monoclonal/therapeutic use ; Clinical Trials, Phase II as Topic ; Colitis, Ulcerative/drug therapy ; Interleukin-23 ; Janus Kinase Inhibitors/adverse effects ; Clinical Trials, Phase III as Topic
    Chemical Substances Antibodies, Monoclonal ; Interleukin-23 ; Janus Kinase Inhibitors
    Language English
    Publishing date 2023-03-07
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 2061369-6
    ISSN 1744-7623 ; 1472-8214
    ISSN (online) 1744-7623
    ISSN 1472-8214
    DOI 10.1080/14728214.2023.2186399
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Advancing transmural remission as a treatment target in Crohn's disease: The future of tight-control strategy?

    D'Amico, Ferdinando / Massironi, Sara / Allocca, Mariangela / Danese, Silvio

    United European gastroenterology journal

    2023  Volume 11, Issue 10, Page(s) 948–950

    MeSH term(s) Humans ; Crohn Disease/diagnosis ; Crohn Disease/drug therapy ; Remission Induction
    Language English
    Publishing date 2023-11-16
    Publishing country England
    Document type Editorial
    ZDB-ID 2728585-6
    ISSN 2050-6414 ; 2050-6406
    ISSN (online) 2050-6414
    ISSN 2050-6406
    DOI 10.1002/ueg2.12495
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Is Selectivity the JAKpot Winner for Inflammatory Bowel Disease Treatment?

    D'Amico, Ferdinando / Peyrin-Biroulet, Laurent / Danese, Silvio

    Gastroenterology

    2022  Volume 163, Issue 6, Page(s) 1482–1484

    MeSH term(s) Humans ; Inflammatory Bowel Diseases/drug therapy
    Language English
    Publishing date 2022-09-22
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 80112-4
    ISSN 1528-0012 ; 0016-5085
    ISSN (online) 1528-0012
    ISSN 0016-5085
    DOI 10.1053/j.gastro.2022.09.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.

    D'Amico, Ferdinando / Peyrin-Biroulet, Laurent / Danese, Silvio

    The New England journal of medicine

    2022  Volume 386, Issue 18, Page(s) 1767–1768

    MeSH term(s) Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/drug therapy ; Humans ; Neoplasms ; Piperidines/adverse effects ; Pyrimidines/adverse effects
    Chemical Substances Piperidines ; Pyrimidines ; tofacitinib (87LA6FU830)
    Language English
    Publishing date 2022-05-03
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 207154-x
    ISSN 1533-4406 ; 0028-4793
    ISSN (online) 1533-4406
    ISSN 0028-4793
    DOI 10.1056/NEJMc2202778
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Endoscopy and histology in inflammatory bowel diseases patients: Complementary or alternatives?

    D'Amico, Ferdinando / Zilli, Alessandra / Fiorino, Gionata

    United European gastroenterology journal

    2022  Volume 10, Issue 2, Page(s) 141–142

    MeSH term(s) Colitis, Ulcerative ; Electronics ; Endoscopy, Gastrointestinal ; Humans ; Inflammatory Bowel Diseases/diagnosis ; Inflammatory Bowel Diseases/pathology
    Language English
    Publishing date 2022-01-22
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 2728585-6
    ISSN 2050-6414 ; 2050-6406
    ISSN (online) 2050-6414
    ISSN 2050-6406
    DOI 10.1002/ueg2.12202
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Could small molecules be used in combination with biologics for inflammatory bowel disease?

    D'Amico, Ferdinando / Danese, Silvio / Fiorino, Gionata

    Expert review of clinical immunology

    2022  Volume 18, Issue 10, Page(s) 991–993

    MeSH term(s) Biological Products/therapeutic use ; Chronic Disease ; Colitis, Ulcerative ; Humans ; Inflammatory Bowel Diseases/drug therapy
    Chemical Substances Biological Products
    Language English
    Publishing date 2022-08-02
    Publishing country England
    Document type Editorial
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2022.2104713
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top